Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Proteros, Priaxon to collaborate on PPIs
May 2013
SHARING OPTIONS:

MUNICH, GermanyŚProteros biostructures GmbH and Priaxon AG have established a lead discovery collaboration for the joint development of lead compounds for high-value protein-protein interaction (PPI) drug targets. Under the agreement, Proteros will apply its integrated lead discovery expertise and technologies in structural biology, biophysics and screening, while Priaxon will make use of Priaxplore, its proprietary drug discovery platform. No financial details were released.
 
"We are very pleased to have formed this relationship with Priaxon. Both companies have complementary platforms as well as an established track record. PPIs are a big challenge in drug discovery and the use of structural information, computational chemistry and Priaxons' validated chemistry approach allows us to respond to the industry demand for such targets in a unique manner," said Dr. Torsten Neuefeind, CEO of Proteros.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.